The Valley Desk

Clinical trial reportAmerican journal of hematologyPublished

DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names University of Pennsylvania. Affiliation source

Publication record

Type
Clinical trial report
Venue
American journal of hematology
Published
Subject terms
Humans; Lymphoma; Neoplasm Recurrence, Local; Organic Chemicals; Thalidomide; Sirolimus; Antineoplastic Combined Chemotherapy Protocols; Protein Kinase Inhibitors; Treatment Outcome; Adult; Aged; Aged, 80 and over
PubMed ID
36810799
Added to directory
Source checked

Report a correction or request removal